Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy

BACKGROUND: Nephrectomy, whether in the era of cytokine therapy or targeted therapy, has an important role in the treatment of metastatic renal cell carcinoma. With the advent of immunotherapy, immunotherapy combined with targeted therapy has become the mainstream of systemic therapy, but the role o...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Hanzhi, Cao, Yuan, Jian, Yan, Lei, Jun, Zhou, Weimin, Yu, Xiaoling, Zhang, Xiquan, Peng, Zhiqiang, Sun, Zhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557339/
https://www.ncbi.nlm.nih.gov/pubmed/37803307
http://dx.doi.org/10.1186/s12885-023-11408-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557339/
https://www.ncbi.nlm.nih.gov/pubmed/37803307
http://dx.doi.org/10.1186/s12885-023-11408-x

Ejemplares similares